Last reviewed · How we verify

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

NCT04929392 PHASE2 ACTIVE_NOT_RECRUITING

This phase II trial studies the effect of chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery in treating patients with esophageal or esophageal/gastroesophageal junction cancer that has not spread to other places in the body (non-metastatic). Pembrolizumab is an immunotherapy drug that works by harnessing the immune system to attack cancer. Lenvatinib is an anti-cancer drug that works by stopping or slowing down the growth of cancer cells. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery may kill more tumor cells.

Details

Lead sponsorCity of Hope Medical Center
PhasePHASE2
StatusACTIVE_NOT_RECRUITING
Enrolment3
Start dateTue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionSun Apr 25 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

United States